Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

David Bolster

Internal Medicine Summerville, SC Medical Doctor

NPI 1144205824 CMS profile 97408

1516 Old Trolley Rd # 101, Summerville, SC 29485

Open in the dashboard

General payments

$6,262

429 records reported · program years 2019–2023

Research payments

$2,039

Paid to them · 12 records reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,336,432 paid to institutions, not to them · program years 2019–2025

Through program year 2023, David Bolster of Summerville, SC is reported in the CMS Open Payments database as having received $6,262 across 429 general payments and $2,039 in research payments paid to them. Separately, studies naming them as principal investigator received $2,336,432 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $168 8
2022 General $1,535 105
2021 General $1,874 128
2020 General $1,048 76
2019 General $1,636 112
2019 Research $2,039 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Bolster
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to David Bolster were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year David Bolster Internal Medicine median Middle half National median
2019 $1,636 $159 $48–$570 $163
2020 $1,048 $119 $33–$402 $114
2021 $1,874 $135 $37–$521 $132
2022 $1,535 $141 $42–$496 $149
2023 $168 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $877 74 payments
  2. Amgen Inc. $671 37 payments
  3. Lilly USA, LLC $453 29 payments
  4. AstraZeneca Pharmaceuticals LP $358 24 payments
  5. Amarin Pharma Inc. $354 26 payments
  6. Novo Nordisk Inc $345 29 payments
  7. Pfizer Inc. $322 23 payments
  8. GlaxoSmithKline, LLC. $322 20 payments
  9. Janssen Pharmaceuticals, Inc $284 20 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $282 19 payments
  11. Other $1,994 128 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $6,229 426 payments
  2. Education $33 3 payments
Products named General payments · program years 2019–2023
  1. Repatha $380 17 payments
  2. VRAYLAR $374 35 payments
  3. TRULICITY $338 22 payments
  4. Vascepa $330 24 payments
  5. JARDIANCE $316 21 payments
  6. Ozempic $292 25 payments
  7. XARELTO $278 19 payments
  8. Otezla $252 11 payments
  9. TRELEGY ELLIPTA $248 15 payments
  10. EVENITY $233 16 payments
  11. Other $5,981 402 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2023
  1. Corcept Therapeutics $1,385 6 payments
  2. AbbVie, Inc. $654 6 payments

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

68

Median for Internal Medicine: 777

Drug cost

$840

Median for Internal Medicine: $73,373

Branded share of claims

0%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sertraline Hcl Generic 11 $303
Levothyroxine Sodium Generic 14 $215
Rosuvastatin Calcium Generic 14 $172
Spironolactone Generic 12 $87
Amlodipine Besylate Generic 17 $63

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

441 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record